barzolvolimab

Home
Ligands
barzolvolimab

GtoPdb Ligand ID: 11607

Synonyms: CDX-0159

Comment: Barzolvolimab (CDX-0159) is a clinical stage humanized anti-KIT IgG1 monoclonal antibody that was developed by Celldex Therapeutics (as claimed in their patent US10781267B2) [1]. CDX-0159 is a variant of CDX-0158 (a.k.a. KTN0158 [2]) that was re-engineered to improve its safety profile and increase its serum half-life. CDX-0158 was originally designed for potential to treat GIST and other KIT-dependent tumours. This original version of the antibody inhibits mutant and wild type KIT phosphorylation, reduces mast cell degranulation and mast cell numbers, and shrinks tumours in a preclinical canine model of spontaneous mast cell tumour development [2].

References
1. Hadari Y, Mandel-Bausch EM Carr FJ, Jones TD, Perry LCA. (2020) Anti-kit antibodies and uses thereof. Patent number: US10781267B2. Assignee: Celldex Therapeutics Inc. Priority date: 25/07/2012. Publication date: 22/09/2020.
2. London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM et al.. (2017) KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clin Cancer Res, 23 (10): 2565-2574. [PMID:27815356]

References

1. Hadari Y, Mandel-Bausch EM Carr FJ, Jones TD, Perry LCA. (2020)
Anti-kit antibodies and uses thereof.
Patent number: US10781267B2. Assignee: Celldex Therapeutics Inc. Priority date: 25/07/2012. Publication date: 22/09/2020.

2. London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM et al.. (2017)
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
Clin Cancer Res, 23 (10): 2565-2574. [PMID:27815356]